Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

801
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Cancer Vaccines01:30

Cancer Vaccines

600
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
600
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Nature medicine·2026
Same author

Redefining radiotherapy: the gut as an active target in Immuno-Oncology.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Single cells and spatial RNA profiling reveal that inflammatory fibroblasts arise from Edil3 stromal cells in the colon after irradiation.

Cell death and differentiation·2026
Same author

[The radio-induced antitumor immune response as a therapeutic target].

Medecine sciences : M/S·2026
Same author

Radiotherapy induces layer-specific molecular and ultrastructural alterations in triple-negative breast cancer spheroids.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Establishment single lung tumors through orthotopic injection.

Methods in cell biology·2026

Related Experiment Video

Updated: Nov 5, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.8K

(Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?

Michele Mondini1, Eric Deutsch1,2

  • 1Gustave Roussy, Université Paris-Saclay, INSERM U1030, Villejuif, France. eric.deutsch@gustaveroussy.fr michele.mondini@gustaveroussy.fr.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 14, 2021
PubMed
Summary

Chemoradiotherapy for cervical cancer alters the tumor immune microenvironment unpredictably. Identifying blood biomarkers is crucial for selecting patients who will benefit from combined immunotherapies.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

920

Related Experiment Videos

Last Updated: Nov 5, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

920

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Chemoradiotherapy (CRT) is an immunogenic cancer treatment.
  • CRT can induce significant, yet heterogeneous, changes in the tumor immune landscape.
  • Cervical cancer treatment often involves CRT, necessitating optimized therapeutic strategies.

Purpose of the Study:

  • To investigate the dynamic changes in the tumor immune microenvironment during CRT for cervical cancer.
  • To identify potential blood-based biomarkers for patient stratification in combined immunotherapy approaches.
  • To provide insights for designing rational, combination immunotherapy strategies post-CRT.

Main Methods:

  • Analysis of tumor immune landscape alterations during CRT in cervical cancer patients.
  • Exploration of blood-based biomarkers for predicting treatment response.
  • Correlation of immune changes with clinical outcomes.

Main Results:

  • Observed heterogeneous immune responses within tumors during chemoradiotherapy.
  • Identified specific immune cell populations and cytokine profiles that vary significantly.
  • Highlighted the potential of certain blood markers to reflect these intratumoral changes.

Conclusions:

  • Chemoradiotherapy's impact on the tumor immune microenvironment is complex and patient-specific.
  • Patient selection based on predictive biomarkers is essential for successful immunotherapy combinations.
  • Blood-based biomarkers offer a promising, non-invasive approach for stratifying cervical cancer patients for immunotherapy.